基于尿液的DNA甲基化标志物检测用于检出上尿路尿路上皮癌:一项前瞻性队列研究
本研究前瞻性纳入50例原发性上尿路尿路上皮癌患者,在根治性肾输尿管切除术、输尿管切除术或输尿管镜检查前采集尿液,用Bladder CARE检测3种癌症标志物(TRNA-Cys、SIM2、NKX1-1)及2个内参位点的甲基化水平,并与1:1性别/年龄匹配的无癌健康个体比较。Bladder CARE Index与肿瘤大小显著相关,上尿路尿路上皮癌患者Index值显著高于对照(均值189.3 vs 1.6,P < .001),灵敏度96%、特异度88%、阳性预测值89%、阴性预测值96%。作者结论认为Bladder CARE是准确的上尿路尿路上皮癌尿液表观遗传学检测,灵敏度远高于标准尿细胞学。
要点
- Bladder CARE Index在上尿路尿路上皮癌患者中显著高于无癌对照(均值189.3 vs 1.6,P < .001)。
- Bladder CARE检测上尿路尿路上皮癌的灵敏度96%、特异度88%、阳性预测值89%、阴性预测值96%。
- 35例有尿细胞学结果的患者中22例(63%)为假阴性。
核心结论
- Bladder CARE是准确的上尿路尿路上皮癌尿液表观遗传学检测,灵敏度远高于标准尿细胞学。
研究设计与样本
- 前瞻性队列研究,经机构审查委员会批准,于2019年12月至2022年3月前瞻性采集原发性上尿路尿路上皮癌患者术前尿液。
- 共纳入50例患者(40例根治性肾输尿管切除术、7例输尿管切除术、3例输尿管镜检查),中位(IQR)年龄72(64-79)岁。
- 结果与1:1性别/年龄匹配的无癌健康个体比较。
主要发现
- Bladder CARE Index结果阳性47例、高风险1例、阴性2例。
- Bladder CARE Index值与肿瘤大小存在显著相关性。
- 上尿路尿路上皮癌患者Bladder CARE Index值显著高于对照(均值189.3 vs 1.6,P < .001)。
- 35例有尿细胞学结果的患者中22例(63%)为假阴性。
- Bladder CARE检测上尿路尿路上皮癌的灵敏度96%、特异度88%、阳性预测值89%、阴性预测值96%。
关键数值与推荐
- Bladder CARE Index结果分类:阳性(>5)、高风险(2.5-5)、阴性(<2.5)。
- Bladder CARE检测3种癌症标志物(TRNA-Cys、SIM2、NKX1-1)及2个内参位点的甲基化水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We explored the accuracy of a urine-based epigenetic test for detecting upper tract urothelial carcinoma. MATERIALS AND METHODS: Under an Institutional Review Board-approved protocol, urine samples were prospectively collected from primary upper tract urothelial carcinoma patients before radical nephroureterectomy, ureterectomy, or ureteroscopy between December 2019 and March 2022. Samples were analyzed with Bladder CARE, a urine-based test that measures the methylation levels of 3 cancer biomarkers (TRNA-Cys, SIM2, and NKX1-1) and 2 internal control loci using methylation-sensitive restriction enzymes coupled with quantitative polymerase chain reaction. Results were reported as the Bladder CARE Index score and quantitatively categorized as positive (>5), high risk (2.5-5), or negative (<2.5). The findings were compared with those of 1:1 sex/age-matched cancer-free healthy individuals. RESULTS: Fifty patients (40 radical nephroureterectomy, 7 ureterectomy, and 3 ureteroscopy) with a median (IQR) age of 72 (64-79) years were included. Bladder CARE Index results were positive in 47, high risk in 1, and negative in 2 patients. A significant correlation was found between Bladder CARE Index values and tumor size. Urine cytology was available for 35 patients, of whom 22 (63%) results were false-negative. Upper tract urothelial carcinoma patients had significantly higher Bladder CARE Index values compared to the controls (mean 189.3 vs 1.6, P < .001). The sensitivity, specificity, positive predictive value, and negative predictive value of the Bladder CARE test for detecting upper tract urothelial carcinoma were 96%, 88%, 89%, and 96%, respectively.Conclusions:Bladder CARE is an accurate urine-based epigenetic test for the diagnosis of upper tract urothelial carcinoma, with much higher sensitivity than standard urine cytology.
引用
- Ghoreifi A, Ladi-Seyedian SS, Piatti P, et al. A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study. J Urol. 2023. PMID: 36795966. doi:10.1097/JU.0000000000003188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。